Tetrasomy 13 as the sole cytogenetic abnormality in acute myeloid leukemia M1 without maturation

Tetrasomy 13 as the sole cytogenetic abnormality in acute myeloid leukemia M1 without maturation

We report a case of acute myeloid leukemia (AML) M1 showing a 48,XY,+13,+13 karyotype. Treatment was according to the Medical Research Council AML14 trial protocol with two courses of DAT chemotherapy. Postchemotherapy bone marrow examination failed to show complete remission or cytogenetic normaliz...

Full description

Saved in:
Bibliographic Details
Published in:Cancer genetics and cytogenetics Vol. 135; no. 2; pp. 192 - 195
Main Authors: McGrattan, Peter, Alexander, H.Denis, Humphreys, Mervyn W., Kettle, Paul J.
Format: Journal Article
Language:English
Published: New York, NY Elsevier Inc 01-06-2002
Elsevier Science
Subjects:
Aneuploidy
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Chromosomes, Human, Pair 13
Cytarabine - administration & dosage
Daunorubicin - administration & dosage
Drug Resistance, Neoplasm
Fatal Outcome
Granulocyte Colony-Stimulating Factor - administration & dosage
Hematologic and hematopoietic diseases
Humans
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - genetics
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Medical sciences
Middle Aged
Thioguanine - administration & dosage
Vidarabine - administration & dosage
Vidarabine - analogs & derivatives
Chromosomal aberration
Antineoplastic agent
Human
Treatment resistance
Pathophysiology
Acute
Treatment efficiency
Chromosome D13
Clinical form
Aneuploidy
Exploration
Malignant hemopathy
Case study
Chemotherapy
Treatment
Death
Acute myelocytic leukemia
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report a case of acute myeloid leukemia (AML) M1 showing a 48,XY,+13,+13 karyotype. Treatment was according to the Medical Research Council AML14 trial protocol with two courses of DAT chemotherapy. Postchemotherapy bone marrow examination failed to show complete remission or cytogenetic normalization. Despite having resistant disease, the patient initially remained clinically well although requiring regular blood transfusions for anemia. However his leukocyte count gradually increased and he became symptomatic. He was treated subsequently with FLAG but died approximately 2 weeks later, 6 months after first presenting. Tetrasomy 13 as the sole cytogenetic abnormality has not been reported previously in M1 AML and has only been reported in three other AML cases, all with an immature phenotype and poor outcome.
Bibliography:ObjectType-Case Study-3
SourceType-Scholarly Journals-1
content type line 23
ObjectType-Review-1
ObjectType-Feature-5
ObjectType-Report-2
ObjectType-Article-4
ISSN:0165-4608
1873-4456
DOI:10.1016/S0165-4608(01)00651-3